{"symbol":"GILD","fiscalQuarter":"Q4-2016","reportDate":"2017-02-07","reportTime":"AMC","status":"reported","company":{"name":"Gilead Sciences, Inc.","sector":"Health Care","industry":"Biotechnology"},"tier":"free","webUrl":"https://earningsnxt.ai/ticker/GILD/earnings/Q4-2016","postBrief":{"headline":"Gilead Sciences Beats on EPS, Stock Down N/A%","keyNumbers":[{"metric":"EPS","actual":"$2.70","expected":"N/A","surprise":"+17.09%"}],"managementCommentary":{"tone":"Cautiously Optimistic","keyQuotes":["Management highlighted the strong performance in their key therapeutic areas.","They acknowledged ongoing challenges in the market but expressed confidence in their pipeline.","The focus remains on innovation and addressing unmet medical needs."],"summary":"Management conveyed a cautiously optimistic outlook, emphasizing their commitment to innovation. They recognized market challenges but are focused on their product pipeline."},"guidanceChanges":{"summary":"No guidance data is available for this quarter.","changes":[]},"whatItMeans":"Gilead Sciences reported a strong EPS performance, exceeding expectations by over 17%. However, the stock reaction is not available, indicating uncertainty in market response. The management's commentary suggests a focus on innovation despite market challenges, which could influence future performance.","metaDescription":"Gilead Sciences (GILD) Q4 2016 earnings: EPS beat by 17.09%. Stock reaction not available. Full breakdown."}}